Cargando…

Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital

OBJECTIVE: Plasma glucose has been correlated with in-hospital mortality among many diseases including infections. We aimed to study the plasma glucose at the admission of hospitalized patients with COVID-19 at a tertiary care referral hospital at Jodhpur, India and its relation with mortality. DESI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Bharat, Mittal, Madhukar, Gopalakrishnan, Maya, Garg, Mahendra K, Misra, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240722/
https://www.ncbi.nlm.nih.gov/pubmed/33971617
http://dx.doi.org/10.1530/EC-21-0086
_version_ 1783715263367086080
author Kumar, Bharat
Mittal, Madhukar
Gopalakrishnan, Maya
Garg, Mahendra K
Misra, Sanjeev
author_facet Kumar, Bharat
Mittal, Madhukar
Gopalakrishnan, Maya
Garg, Mahendra K
Misra, Sanjeev
author_sort Kumar, Bharat
collection PubMed
description OBJECTIVE: Plasma glucose has been correlated with in-hospital mortality among many diseases including infections. We aimed to study the plasma glucose at the admission of hospitalized patients with COVID-19 at a tertiary care referral hospital at Jodhpur, India and its relation with mortality. DESIGN: A hospital-based clinical study of plasma glucose of COVID-19 patients conducted from May 15 to June 30, 2020 after ethical approval. MEASUREMENTS: Random blood samples at admission were collected for plasma glucose, interleukin-6 (IL6) and high sensitivity C-reactive protein (hsCRP) after written informed consent was obtained. Plasma glucose was analyzed by the automated analyzer, IL6 by chemiluminescent immunoassay and hsCRP by immune-turbidimetric assay. RESULTS: A total of 386 patients were studied (female 39.6%); 11.1% had severe disease and 4.1% expired. There were 67 (17.4%) patients with known diabetes mellitus (DM). Patients with a history of DM had three times higher mortality (6/67, 9%) than those without DM (10/309, 3.1%). Patients with moderate and severe disease according to ICMR and WHO grading had higher plasma glucose than those with asymptomatic or mild disease (P < 0.0001). Plasma glucose levels at admission were significantly higher in non-survivors when compared to those who survived (297 ± 117 vs 131 ± 73; P < 0.0001). COVID-19 patients showed increased mortality with incremental plasma glucose levels. The hazard ratio for mortality was 1.128 (95% CI 0.86–14.860), 1.883 (95% CI 0.209–16.970), and 4.005 (95% CI 0.503–32.677) in random plasma glucose group of >100–200, >200–300 and >300 mg/dL, respectively, compared to those with random plasma glucose of <100 mg/dL at admission. Plasma glucose was strongly correlated with hsCRP (P < 0.001) and IL6 (P < 0.0001). CONCLUSIONS: Plasma glucose at admission in hospitalized COVID-19 patients is a strong predictor of mortality.
format Online
Article
Text
id pubmed-8240722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-82407222021-07-01 Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital Kumar, Bharat Mittal, Madhukar Gopalakrishnan, Maya Garg, Mahendra K Misra, Sanjeev Endocr Connect Research OBJECTIVE: Plasma glucose has been correlated with in-hospital mortality among many diseases including infections. We aimed to study the plasma glucose at the admission of hospitalized patients with COVID-19 at a tertiary care referral hospital at Jodhpur, India and its relation with mortality. DESIGN: A hospital-based clinical study of plasma glucose of COVID-19 patients conducted from May 15 to June 30, 2020 after ethical approval. MEASUREMENTS: Random blood samples at admission were collected for plasma glucose, interleukin-6 (IL6) and high sensitivity C-reactive protein (hsCRP) after written informed consent was obtained. Plasma glucose was analyzed by the automated analyzer, IL6 by chemiluminescent immunoassay and hsCRP by immune-turbidimetric assay. RESULTS: A total of 386 patients were studied (female 39.6%); 11.1% had severe disease and 4.1% expired. There were 67 (17.4%) patients with known diabetes mellitus (DM). Patients with a history of DM had three times higher mortality (6/67, 9%) than those without DM (10/309, 3.1%). Patients with moderate and severe disease according to ICMR and WHO grading had higher plasma glucose than those with asymptomatic or mild disease (P < 0.0001). Plasma glucose levels at admission were significantly higher in non-survivors when compared to those who survived (297 ± 117 vs 131 ± 73; P < 0.0001). COVID-19 patients showed increased mortality with incremental plasma glucose levels. The hazard ratio for mortality was 1.128 (95% CI 0.86–14.860), 1.883 (95% CI 0.209–16.970), and 4.005 (95% CI 0.503–32.677) in random plasma glucose group of >100–200, >200–300 and >300 mg/dL, respectively, compared to those with random plasma glucose of <100 mg/dL at admission. Plasma glucose was strongly correlated with hsCRP (P < 0.001) and IL6 (P < 0.0001). CONCLUSIONS: Plasma glucose at admission in hospitalized COVID-19 patients is a strong predictor of mortality. Bioscientifica Ltd 2021-05-06 /pmc/articles/PMC8240722/ /pubmed/33971617 http://dx.doi.org/10.1530/EC-21-0086 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Research
Kumar, Bharat
Mittal, Madhukar
Gopalakrishnan, Maya
Garg, Mahendra K
Misra, Sanjeev
Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title_full Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title_fullStr Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title_full_unstemmed Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title_short Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital
title_sort effect of plasma glucose at admission on covid-19 mortality: experience from a tertiary hospital
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240722/
https://www.ncbi.nlm.nih.gov/pubmed/33971617
http://dx.doi.org/10.1530/EC-21-0086
work_keys_str_mv AT kumarbharat effectofplasmaglucoseatadmissiononcovid19mortalityexperiencefromatertiaryhospital
AT mittalmadhukar effectofplasmaglucoseatadmissiononcovid19mortalityexperiencefromatertiaryhospital
AT gopalakrishnanmaya effectofplasmaglucoseatadmissiononcovid19mortalityexperiencefromatertiaryhospital
AT gargmahendrak effectofplasmaglucoseatadmissiononcovid19mortalityexperiencefromatertiaryhospital
AT misrasanjeev effectofplasmaglucoseatadmissiononcovid19mortalityexperiencefromatertiaryhospital